GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Forian Inc (NAS:FORA) » Definitions » EBITDA Margin %

Forian (Forian) EBITDA Margin % : -18.39% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Forian EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Forian's EBITDA for the three months ended in Mar. 2024 was $-0.90 Mil. Forian's Revenue for the three months ended in Mar. 2024 was $4.88 Mil. Therefore, Forian's EBITDA margin for the quarter that ended in Mar. 2024 was -18.39%.


Forian EBITDA Margin % Historical Data

The historical data trend for Forian's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forian EBITDA Margin % Chart

Forian Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- -912.29 -142.16 -111.19 13.43

Forian Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.39 -16.80 107.97 -4.38 -18.39

Competitive Comparison of Forian's EBITDA Margin %

For the Health Information Services subindustry, Forian's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forian's EBITDA Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Forian's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Forian's EBITDA Margin % falls into.



Forian EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Forian's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=2.75/20.481
=13.43 %

Forian's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-0.897/4.877
=-18.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forian  (NAS:FORA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Forian EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Forian's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Forian (Forian) Business Description

Traded in Other Exchanges
N/A
Address
41 University Drive, Suite 400, Newtown, PA, USA, 18940
Forian Inc provides a suite of SaaS solutions, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries, manufacturers, cultivators, and regulators.
Executives
Martin J Wygod director P.O. BOX 676306, RANCHO SANTA FE CA 92067
Trotman Stanley S Jr director
Max C Wygod director, officer: Executive Chairman 41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Max Wygod Family Dynasty Trust 10 percent owner 41 UNIVERSITY DRIVE, SUITE 400, NEWTOWN PA 18940
Michael Vesey officer: Chief Financial Officer 4041-T HADLEY ROAD, S. PLAINFIELD NJ 07080
Jennifer Hajj director 41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Scott Matthew Ogur director C/O HELIX TCS, INC., 10200 E. GIRARD AVENUE, SUITE B420, DENVER CO 80231
Farren Clifford A Jr officer: Chief Financial Officer C/O SYNAVANT INC, 3445 PEACHTREE ROAD NE SUITE 1400, ATLANTA GA 30326
Adler Mark J Md director
Ian Banwell director P.O. BOX 34004, CHARLOTTE NC 28234
Shahir Kassam-adams director 41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Adam H Dublin director, officer: Chief Strategy Officer 41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Daniel J Barton director, officer: Chief Executive Officer 41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Alyssa F Varadhan director 41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940